Holen Sie sich die Stockscreener-App
2.45
2.39%
-0.06
Handel nachbörslich:
2.48
0.03
+1.22%
Schlusskurs vom Vortag:
$2.51
Offen:
$2.57
24-Stunden-Volumen:
13,696
Relative Volume:
1.06
Marktkapitalisierung:
$70.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-7.55%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.45
$2.59
1-Wochen-Bereich:
$2.3312
$2.71
52-Wochen-Spanne:
$2.3312
$3.09
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Firmenname
Insight Molecular Diagnostics Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Vergleichen Sie IMDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
2.45 | 71.78M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 180.28B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 147.31B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.92 | 52.18B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 33.33B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 31.60B | 15.50B | 1.33B | 2.16B | 7.34 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Eingeleitet | Lake Street | Buy |
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest
Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com
Needham reiterates Buy rating on Insight Molecular Diagnostics stock By Investing.com - Investing.com UK
Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - Santé log
Insight Molecular Diagnostics: Q2 Earnings Snapshot - San Francisco Chronicle
Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com
Insight Molecular Diagnostics Reports Q2 Loss of $9.7 Million - AInvest
IMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - 富途牛牛
Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc.Common Stock (Nasdaq:IMDX) Stock Quote - FinancialContent
Molecular Diagnostics Market Overview: Growth Factors to 2035 - MarketReports.us
PCR Molecular Diagnostics Market Global Forecast 2025–2032: Sector-Wise Insights - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 8.81% premarket after QIAGEN's solid Q2 2025 results. - AInvest
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - The Manila Times
iMDx to Release Second Quarter 2025 Results on August 11, - GlobeNewswire
iMDx Announces Two Major Investor Events: Q2 Earnings and Needham Conference Back-to-Back - Stock Titan
Diagnostic Contract Manufacturing Market Forecast 2025–2034: Key Metrics and Strategic Insights - WhaTech
IMDX World Transplant Congress Late-Breaking Data - GlobeNewswire
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients - Yahoo Finance
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
iMDx to Host Virtual KOL Event to Discuss its In-House - GlobeNewswire
Vanderbilt Professor Reveals Game-Changing In-House Kidney Transplant Testing Technology at Expert Event - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 3.16% intraday as ImmunoPrecise Antibodies Ltd. announces new findings. - AInvest
Insight Molecular Diagnostics Inc. shares rise 5.32% premarket after Seegene unveils new diagnostic system and data analytics platform. - AInvest
Insight Molecular Diagnostics Insiders Increase Holdings Amidst Bullish Bets - AInvest
Insight Molecular Diagnostics Insiders Placed Bullish Bets Worth US$2.82m - Yahoo Finance
U.S. In Vitro Diagnostics (IVD) Market and Competition - GlobeNewswire
U.S. In Vitro Diagnostics (IVD) Market and Competition Insights 2025-2034Next-Gen Genomic Tools and Decentralized Testing to Transform U.S. Diagnostics Landscape - Yahoo.co
Clinical Laboratory Services Market Expanding with Diagnostic Testing Growth and Automation Advancements - newstrail.com
Sepsis Diagnostics Market: Global Industry Overview, Trends, Challenges, and Regional Insights - PharmiWeb.com
Insight Molecular Diagnostics Inc. shares rise 1.24% intraday after Agilent Technologies and Oxford BioDynamics host webinar on 3D genomic biomarker discovery. - AInvest
Proteinase K Market Grows Amid Rising Demand for Molecular Research and Diagnostics - newstrail.com
Companion Diagnostic Technologies Market Watch: Strategic Forecasts Amid Rising Economic Volatility - newstrail.com
IVD Contract Manufacturing Services Market Watch: Strategic Forecasts Amid Rising Economic Volatility - newstrail.com
Molecular Diagnostics Market Future Business Opportunities 2025-2032 | USD 27.8 billion by 2032, CAGR of 9.1% - newstrail.com
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk - TradingView
Molecular Diagnostics Market Booming as Precision Medicine, - openPR.com
Liver Cancer Diagnostics Market Analysis 2025–2035 | Trends, Technologies & Regional Insights - PharmiWeb.com
Molecular Diagnostics Reagent Market Driven by Rising Infectious Diseases and Genetic Testing - openPR.com
Oncocyte Relocates HQ from Irvine to Nashville - Orange County Business Journal
Insight Molecular Diagnostics Approves Key Proposals at Annual Meeting - TipRanks
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics - PR Newswire
Insight Molecular Diagnostics Inc.(NasdaqCM:IMDX) dropped from Russell 3000E Growth Index - MarketScreener
Revolutionizing Healthcare: Molecular Diagnostics Market Set - openPR.com
What's Driving the Future of the Molecular Cytogenetics Market? - openPR.com
Early cancer detection company opening U.S. headquarters in Franklin - Nashville Post
Oncology Molecular Diagnostics Market in Flux: Recession Signals, Tariff Pressures & Strategic Forecasts - newstrail.com
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate - Yahoo Finance
Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)
Es liegen keine Finanzdaten für Insight Molecular Diagnostics Inc (IMDX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.96%
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):